ClinicalTrials.gg
RecruitingNCT06972056Updated Nov 13, 2026

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

A Phase 4 interventional study of Atogepant 60 mg and Propranolol 160 mg in Migraine, sponsored by Mayo Clinic. Recruiting at 39 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 13, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,335
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Planned enrollment
2nd of 21
1,335 · median 468
Started
2025
with 2 others
Phase 4
4 of 21
3 open now
Registered
19th of 21
by date
Lead sponsor
1 of 21
Mayo Clinic

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2025, is one of 4 in phase 4, and was the 19th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This goal of this study is to compare three medications used for migraine preventive treatment.

This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.

Research participants will:

  • Be randomly assigned to one of the three medications.
  • Provide information about their migraine pattern using a daily headache diary and during research visits.
Read the detailed description

This is a prospective, randomized, comparative effectiveness clinical trial of atogepant, propranolol, and topiramate for the prevention of migraine in adults.

Eligible participants will provide information in a daily headache diary for four weeks. If after those four weeks they are still eligible for the study, they will be randomized to one of the study medications and receive study medication for twelve weeks.

Research visits occur at baseline, four weeks later for the randomization visit, and then at post-randomization weeks four, eight, twelve, twenty-four, and forty-eight.

Participants provide data using a headache diary (first 16 weeks of the study) and during research visits.

The primary endpoint is the proportion of participants in each treatment group who are "treatment responders" defined as completing the first twelve weeks of the study on the assigned medication and having a 50% or greater reduction in moderate severe headache days during weeks 9-12 post-randomization compared to the four weeks pre-randomization.

03

Conditions studied

  • Migraine

Keywords

  • Migraine
  • Migraine with aura
  • Migraine prevention
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults, 18-70 years of age at the time of enrollment
  • Migraine with aura, migraine without aura, and/or chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)
  • Migraine onset prior to 50 years of age
  • Migraine present for at least 12 months at the time of enrollment
  • At least four "moderate to severe headache days" per month (by patient self-report and then confirmed during four-week pre-randomization headache diary phase) A "moderate to severe headache day" is defined as a day during which there is a headache of moderate to severe intensity that lasts for at least four hours, or a day on which a migraine-specific acute medication is taken to treat headache.
  • If already taking a migraine preventive treatment, willing to continue with that treatment without dose change during the first 16 weeks of the study, including the 4-week run-in phase and 12-week randomized phase.
  • Not pregnant or breastfeeding
  • Women of must agree to use effective methods of to reduce the risk of pregnancy.
  • Willingness and ability to provide .
  • Willingness and ability to complete all research visits.

Exclusion criteria

Exclusion Criteria:

  • to taking atogepant, propranolol, or topiramate.
  • Currently taking atogepant, propranolol, or topiramate*
  • Previously took atogepant, propranolol, or topiramate*
  • Unwillingness to take atogepant, topiramate, or propranolol.
  • Current use of a CGRP-targeting preventive medication or beta-blocker
  • Migraine with brainstem aura
  • Hemiplegic migraine
  • Retinal migraine
  • Migraine aura without headache (exclusively)
  • Pure menstrual migraine
  • Trigeminal autonomic cephalalgias
  • Facial neuralgias
  • Secondary headache disorders (medication overuse headache is not an exclusion)
  • Migraine preventive treatment has been started or dose has been changed within 12 weeks prior to potential enrollment.
  • Used opioids or butalbital on five or more days per month on average for at least 3 months prior to enrollment.
  • Current or past epilepsy
  • Severe hepatic impairment
  • Moderate or more severe renal impairment * Occasional as needed use of propranolol, currently or in the past, is not an exclusion, such as taking as needed propranolol for treatment of anxiety.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,335 participants (estimated)

Study arms

  • Active comparator
    Atogepant

    Participants who are randomized to this arm will take up to 60mg daily for 12 weeks.

    Drug: Atogepant 60 mg

  • Active comparator
    Propranolol

    Participants randomized to this arm will take up to 160 mg daily for 12 weeks.

    Drug: Propranolol 160 mg

  • Active comparator
    Topiramate

    Participants randomized to this arm will take up to 100 mg daily for 12 weeks .

    Drug: Topiramate 100 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment Responder (atogepant vs. topiramate; atogepant vs. propranolol)

    This study will use a "treatment responder" primary endpoint that will investigate medication superiority using a combination of headache frequency reduction and medication persistence. To achieve this, a binary endpoint of treatment response will be used that combines effectiveness and medication persistence at the individual level, with success defined as: 1. Completing the first 12 weeks of the study on the assigned medication without discontinuation due to any reason, AND 2. Having a 50% or greater reduction in moderate to severe headache days during weeks 9-12 compared to a 4-week pre-randomization period.

    Time frame: Weeks 9-12 post-randomization compared to the 4 weeks prior to randomization

Secondary outcomes

  1. Migraine Specific Quality-of-Life - Role Function-Restrictive

    The role function-restrictive domain of the Migraine Specific Quality of Life questionnaire is a 7-item valid measure of functional impact of migraine on work or daily activities, relationships with family and friends, leisure time, productivity, concentration, energy, and tiredness during the past four weeks.

    Time frame: Week 12 post-randomization vs. baseline

  2. Treatment Responder (propranolol vs. topiramate)

    This study will use a "treatment responder" primary endpoint that will investigate medication superiority using a combination of headache frequency reduction and medication persistence. To achieve this, a binary endpoint of treatment response will be used that combines effectiveness and medication persistence at the individual level, with success defined as: 1. Completing the first 12 weeks of the study on the assigned medication without discontinuation due to any reason, AND 2. Having a 50% or greater reduction in moderate to severe headache days during weeks 9-12 compared to a 4-week pre-randomization period.

    Time frame: Weeks 9-12 post-randomization vs. the 4 weeks prior to randomization

  3. Headache Impact Test-6 (HIT-6)

    The HIT-6 is a six-item questionnaire that measures the impact headaches have on a person's ability to function on the job, at home, at school, and in social situations.

    Time frame: week 12 post-randomization vs. baseline

  4. Medication-Related Adverse Events

    This medication-related adverse event outcome will consist of all adverse events that are deemed to be at least possibly related to the study medication.

    Time frame: All 12 weeks of the randomized treatment phase

07

Study locations

36 of 39 sites recruiting
  • Apogee Clinical Research
    Hazel Green, Alabama 35750, United States
    Not yet recruiting
    • Shelby Lessman · Contactslessmann@apogeecr.com · 256-827-5050
    • Jesslyn Roesch · Contactjroesch@apogeecr.com · 256-827-5050
    • Laura L Taylor, MD · Principal investigator
    • Viktoriya Nelson, MD · Sub investigator
  • Northern Arizona Healthcare
    Flagstaff, Arizona 86001, United States
    Recruiting
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
    Recruiting
    • Dani C Smith, MS · ContactSmith.Dani@Mayo.edu · 480-342-6524
    • Michael Leonard, MDiv · ContactLeonard.Michael@Mayo.edu · 480-342-2908
    • Todd Schwedt, MD · Principal investigator
    • Juliana VanderPluym, MD · Sub investigator
  • Keck School of Medicine of USC
    Los Angeles, California 90033, United States
    Recruiting
    • Rama Koppula · Contactrk_198@usc.edu · 323-865-1020
    • Soma Sahai-Srivastava, MD · Principal investigator
    • Gautum Ganguly, MD · Sub investigator
    • Ana Gjurgevich, NP-C · Sub investigator
    • Hawa Mapara, NP-C · Sub investigator
  • Clinical Research Institute
    Los Angeles, California 90048, United States
    Recruiting
  • Desert Physicians Medical Group
    Palm Springs, California 92262, United States
    Recruiting
    • Cindy Ramirez · ContactInfo@dpmgcr.com · 760-459-2193
    • Dario Kuzmanovic · Contactinfo@dpmghealth.com · 909-547-7178
    • Gemma Kim, MD · Principal investigator
    • Andy Tran, MD · Sub investigator
    • Luanne Carlson, DO · Sub investigator
    • Julius Yorac, NP · Sub investigator
  • The Neurology Group
    Pomona, California 91767, United States
    Recruiting
    • Ikram Rfifa, BS · Contactikram@amctrials.com · 951-768-2352
    • Sheraz Mossa, BS · ContactSheraz@amctrials.com · 858-761-1090
    • Samer Kebbeh, MD · Principal investigator
    • Bhupat Desai, MD · Sub investigator
    • Allegra Danna-Demott, PAC · Sub investigator
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
    • Adam Angelich · Contactadam.angelich@cuanschutz.edu · 303-724-5923
    • Trey Jouard · ContactTREY.JOUARD@CUANSCHUTZ.EDU · 303-724-0920
    • Nicole Caunt, MD · Principal investigator
    • Danilee WIlhour, MD · Sub investigator
    • John Kyle Jenkins, MD · Sub investigator
    • Pauline Sok, NP · Sub investigator
    • Marius Birlea, MD · Sub investigator
  • Memorial Healthcare
    Hollywood, Florida 33021, United States
    Recruiting
    • Elisa Serantes · Contactelserantes@mhs.net · 954 265-4184
    • Piret Baldwin · ContactPibaldwin@mhs.net · 954-265-6653
    • Maike Blaya, MD · Principal investigator
    • Brigitte E Farnsworth, MD · Sub investigator
  • Mayo Clinic Florida
    Jacksonville, Florida 32066, United States
    Recruiting
  • Apple Med Research
    Miami, Florida 33126, United States
    Recruiting
  • University of Miami
    Miami, Florida 33136, United States
    Recruiting
    • Lilli Resto · ContactLxr1013@miami.edu · 305-243-1485
    • Daniella Estevez · Contactd.estevez1@miami.edu · 305-243-1485
    • Teshamae Monteith, MD · Principal investigator
    • Liza Smirnoff, MD · Sub investigator
    • Alexandra Cocores, MD · Sub investigator
  • Indiana University
    Indianapolis, Indiana 46202, United States
    Not yet recruiting
    • Jill Mazurczyk · Contactjmazurcz@iu.edu
    • Patricia Olson, MD · Principal investigator
  • Neuroscience Research Center
    Overland Park, Kansas 66210, United States
    Recruiting
  • Clinical Trials of New England
    Hyde Park, Massachusetts 02136, United States
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Terrell Rieken · Contactrieken.terrell@mayo.edu · 507-422-6561
    • Izzie Meunier · ContactHeadlee.Amy@mayo.edu · 507-538-6337
    • Chia-Chun Chiang, MD · Principal investigator
    • Narayan Kissoon, MD · Sub investigator
  • Washington University St Louis
    St Louis, Missouri 63110, United States
    Recruiting
  • Nebraska Medical Center
    Omaha, Nebraska 68198, United States
    Recruiting
    • Jana Ocken · Contactjocken@unmc.edu · 402-552-2672
    • Morgan Hurtz · Contactmhurtz@unmc.edu · 402-552-6233
    • Beth Hartman, MD · Principal investigator
    • Autumn Nye, APRN · Sub investigator
    • Melissa Donnelly, PA · Sub investigator
  • Advanced Research Institute Reno
    Reno, Nevada 89511, United States
    Recruiting
  • JFK Neuroscience Institute
    Edison, New Jersey 08820, United States
    Recruiting
    • Priyanka Basnet, BSN, RN · Contactpriyanka.basnet@hmhn.org · 732-321-7010
    • Shriya Patel · Contactshp228@lehigh.edu
    • Brian Gerhardstein, MD · Principal investigator
    • Emad Noor, MD · Sub investigator
    • Dipakkumar Pandya, MD · Sub investigator
    • Karishma Patel, PA · Sub investigator
  • Nuvance Health Institute
    Kingston, New York 12401, United States
    Recruiting
  • Northwell Health
    Manhasset, New York 11030, United States
    Recruiting
  • Mt Sinai Icahn School of Medicine
    New York, New York 10029, United States
    Recruiting
    • Sarah Kurtz, PA-C · Contactsarah.kurtz@mssm.edu · 917-273-1674
    • Maya Campbell · ContactMaya.campbell@mssm.edu
    • Bridget Mueller, MD · Principal investigator
    • Anna Pace, MD · Sub investigator
    • Tanesha Kemble, DNP FNP-BC · Sub investigator
  • Onsite Clinical Solutions Park Cedar Dr.
    Charlotte, North Carolina 28210, United States
    Recruiting
  • Onsite Clinical Solutions Mecklenburg
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Onsite Clinical Solutions Ballantyne
    Charlotte, North Carolina 28277, United States
    Recruiting
  • Onsite Clinical Solutions Salisbury
    Salisbury, North Carolina 28144, United States
    Recruiting
  • Wake Forest University Health
    Winston-Salem, North Carolina 27157, United States
    Recruiting
  • Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
    Recruiting
  • Advanced Research Institute
    Portland, Oregon 97223, United States
    Recruiting
    • Jessica Weed · Contactjessicaw@advresearch.org · 503-610-0033
    • Rachael Widner · Contactrachael@advresearch.org · 503-610-0033
    • Walter Goebel, MD · Principal investigator
    • Jim Bergthold, MD · Sub investigator
    • John Nguyen, MD · Sub investigator
    • Anantha Jujjuri, PA · Sub investigator
    • Amal Habib Mohamed Jawad Ali Al Yusuf, MD · Sub investigator
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Brown University Health
    Providence, Rhode Island 02903, United States
    Recruiting
  • Vanderbilt Medical Center
    Nashville, Tennessee 37215, United States
    Recruiting
    • Jordon Winn · ContactJordon.winn@vumc.org · 615-421-6094
    • Joy Derwenskus, MD · Principal investigator
    • Francesca Bagnato, MS · Sub investigator
  • DHR Health Headache Center
    McAllen, Texas 78504, United States
    Recruiting
  • Advanced Research Institute Ogden
    Ogden, Utah 84405, United States
    Recruiting
    • Stephanie Church · Contactstephanie@advresearch.org · 801-409-2040
    • Noah Nielsen · Contactnoah@advresearch.org · 801-409-2040
    • Michael Woolman, MD · Principal investigator
    • Jonathan N Winkfield, PA-C · Sub investigator
    • Abbey Coburn, PA-C · Sub investigator
    • Khaldoun M Al-Rayess, MD · Sub investigator
    • Christopher L. Davis, DO · Sub investigator
    • Lynae C Sorensen, MSN AP FNP-C · Sub investigator
    • Michael D DeLange, MD · Sub investigator
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
    Not yet recruiting
  • West Virginia University
    Morgantown, West Virginia 26506, United States
    Recruiting
    • Lauren Chase RN, BSN · Contactlauren.chase@wvumedicine.org · 304-598-4000
    • Bethany Moore, PharmD · ContactBethany.moore2@wvumedicine.org
    • Kristina Lopez, MD · Principal investigator
    • David Watson, MD · Sub investigator
    • Tiffany Lannan, FNP-BC · Sub investigator
    • Heather Hickman, FNP-BC · Sub investigator
    • Lindsey S Keczan, FNP-BC · Sub investigator
    • Sakshi Kaul, DO · Sub investigator
  • Marshfield Clinic Research Institute
    Marshfield, Wisconsin 54449, United States
    Recruiting
  • The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Karen Schmidt, RN · Contactkaschmidt@mcw.edu · (414) 955-0674
    • Victoria Ochotnicky · Contactvochotnicky@mcw.edu · (414) 955-0659
    • Glen Soloman, MD · Principal investigator
    • James Murtha, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — As per PCORI data sharing policy

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Summer 2030 (anticipated)

Access criteria: Per PCORI data sharing policy

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2029, 43 months after the start.

Of 49 non-industry phase 4 interventional studies under Migraine Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 43 months is above that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 14, 2025
StartActual
Jul 9, 2025
Primary completionEst.
Mar 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Apogee Clinical Research · Hazel Green, United States
  • Indiana University · Indianapolis, United States
  • University of Vermont Medical Center · Burlington, United States
across 2 updates, Oct 19, 2026 – Nov 13, 2026
Site contacts
Changed at 8 sites. See the sites
Show 8 sites
  • Desert Physicians Medical Group · Palm Springs, United StatesContact c•••@dpmgcr.com→I•••@dpmgcr.comContact d•••@dpmghealth.com→i•••@dpmghealth.com
  • Clinical Trials of New England · Hyde Park, United StatesContact added W•••@clinicaltrialsne.com
  • Onsite Clinical Solutions Park Cedar Dr. · Charlotte, United StatesContact r•••@onsiteclinical.com · •••3150→S•••@onsiteclinical.com · •••3150
  • Onsite Clinical Solutions Ballantyne · Charlotte, United StatesContact r•••@onsiteclinical.com · •••3150→s•••@onsiteclinical.com · •••3150
  • Wake Forest University Health · Winston-Salem, United StatesContact T•••@advocatehealth.org · •••3861→J•••@advocatehealth.org · •••1715
  • West Virginia University · Morgantown, United StatesContact B•••@wvumedicine.org→B•••@wvumedicine.orgContact person changed (no phone or email listed)
  • Onsite Clinical Solutions Mecklenburg · Charlotte, United StatesContact m•••@onsiteclinical.com · •••3150→j•••@onsiteclinical.com · •••3150
  • Onsite Clinical Solutions Salisbury · Salisbury, United StatesContact a•••@onsiteclinical.com · •••3150→d•••@onsiteclinical.com · •••3150
across 2 updates, Oct 19, 2026 – Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    2 sites added
    Show 2 added (2 United States)
    • Indiana University · Indianapolis, United States
    • University of Vermont Medical Center · Burlington, United States
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Desert Physicians Medical Group · Palm Springs, United StatesContact c•••@dpmgcr.com→I•••@dpmgcr.comContact d•••@dpmghealth.com→i•••@dpmghealth.com
    • Onsite Clinical Solutions Mecklenburg · Charlotte, United StatesContact m•••@onsiteclinical.com · •••3150→j•••@onsiteclinical.com · •••3150
    • Onsite Clinical Solutions Salisbury · Salisbury, United StatesContact a•••@onsiteclinical.com · •••3150→d•••@onsiteclinical.com · •••3150
    • West Virginia University · Morgantown, United StatesContact B•••@wvumedicine.org→B•••@wvumedicine.orgContact person changed (no phone or email listed)
  2. Oct 19, 2026
    1 site added
    Show site
    • Apogee Clinical Research · Hazel Green, United States
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Desert Physicians Medical Group · Palm Springs, United StatesContact a•••@dpmgcr.com · •••7178→c•••@dpmgcr.com · •••2193
    • Clinical Trials of New England · Hyde Park, United StatesContact added W•••@clinicaltrialsne.com
    • Onsite Clinical Solutions Park Cedar Dr. · Charlotte, United StatesContact r•••@onsiteclinical.com · •••3150→S•••@onsiteclinical.com · •••3150
    • Onsite Clinical Solutions Ballantyne · Charlotte, United StatesContact r•••@onsiteclinical.com · •••3150→s•••@onsiteclinical.com · •••3150
    • Wake Forest University Health · Winston-Salem, United StatesContact T•••@advocatehealth.org · •••3861→J•••@advocatehealth.org · •••1715
    • West Virginia University · Morgantown, United StatesContact added (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06972056
Lead sponsor
Mayo Clinic
Collaborators
University of Iowa, Patient-Centered Outcomes Research Institute, AbbVie
Responsible party
Todd J. Schwedt (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
May 14, 2025
Start date
Jul 9, 2025
Primary completion
Mar 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Michael R Leonard, MDiv
Contact
ARZAPTTrial@mayo.edu
480-342-2908
Dani C Smith, M.S.
Contact
Smith.Dani@Mayo.edu
Todd J Schwedt, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atogepant · Propranolol · Topiramate

Start the discussion